Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab PK in children with asthma
NCT04673630Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2021
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of tezepelumab in asthma, sponsored by AstraZeneca. Primary endpoints: Maximum Observed Serum Concentration at Day 85, Time to Achieve Maximum Observed Serum Concentration at Day 85 and 6 more. Started Feb 2021; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04673630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04673630.